Carbomedics® Valve in Congenital Heart Disease: Midterm follow-up study of 14 patients

In 14 patients aged 5-329 (mean 131) months a CarboMedics(R) valve was implanted because of congenital heart disease. The preoperative NYHA function class was III-IV ten cases. Seven aortic and seven atrioventricular valves were replaced without early mortality. All patients were followed up, with mean observation time 27 months (total 384 months). One of the 14 patients died of heart failure 10 months postoperatively. Thrombosis occurred in four valves, three in tricuspid and one in mitral position. In all patients who received only warfarin, anticoagulation was demonstrably inadequate. Consequently we now recommend antiplatelet medication in addition to warfarin for children with atrioventricular mechanical valve replacement. In our experience the complication rate with CarboMedics prosthesis is acceptable, provided that anticoagulant therapy is adequate.